MedPath

The influence of polymorphism in methotrexate pathway genes on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis

Not Applicable
Conditions
Articular-type juvenile idiopathic arthritis (JIA)
Registration Number
JPRN-UMIN000002931
Lead Sponsor
Department of Pediatrics, Yokohama City University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

The patient who was judged by physicians as an improper case for enrollment in this study

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Efficacy and toxicity of methotrexate in patients with JIA
Secondary Outcome Measures
NameTimeMethod
Subgroup analysis based on (1)time interval between onset and treatment, (2)response to therapy, (3)the level of anti-citrullinated peptide antibodies, and rheumatoid factor.
© Copyright 2025. All Rights Reserved by MedPath